The idea of losing weight without daily injections or pills may soon move from science fiction to reality. Biotech companies are developing experimental gene therapies that could transform obesity treatment from a lifelong regimen into a single intervention.
At the forefront is Massachusetts-based Fractyl Health, which is advancing its gene therapy candidate, Rejuva. The therapy aims to reprogram the body’s own cells to produce glucagon-like peptide-1 (GLP-1) hormones, critical regulators of appetite and metabolism. Unlike conventional GLP-1 medications, which require repeated dosing, a single injection of Rejuva instructs pancreatic cells to manufacture GLP-1 adaptively.
Early in vivo studies have shown promising results, paving the way for Phase I clinical trials.
The Limitations of Current GLP-1 Drugs
GLP-1 receptor agonists, such as semaglutide (Ozempic and Wegovy), have reshaped obesity care, helping millions achieve significant weight loss. However, adherence remains a major challenge: research indicates that roughly 50% of patients discontinue treatment within a year, often due to side effects, cost, or insurance limitations. Weight tends to return rapidly once therapy stops.
Production of GLP-1 drugs is also resource-intensive, requiring significantly more solvent than other synthetic compounds. Fractyl hopes Rejuva will overcome these issues by offering a one-time, long-lasting therapy.
How Rejuva Works
Rejuva uses adeno-associated virus (AAV) vectors to deliver genetic instructions to pancreatic beta cells, which normally produce insulin. Reprogrammed cells then produce GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), mimicking the dual-action approach of Eli Lilly’s tirzepatide. The therapy is designed for “nutrient-responsive expression,” increasing hormone production when blood sugar rises and tapering off when it falls, potentially reducing side effects compared to injectable drugs.
Fractyl’s first candidate, RJVA-001, targets type II diabetes and is slated for human trials in 2026. RJVA-002, focused on obesity, demonstrated in preclinical studies with diet-induced obese mice a roughly 30% weight loss over five weeks with no observed adverse effects.
“These data support our GLP-1 gene therapy platform and suggest dual gut hormone expression can produce powerful metabolic effects,” said Fractyl CEO Harith Rajagopalan.
The Competitive Landscape
Fractyl is not alone in exploring genetic approaches to obesity. Arrowhead Pharmaceuticals is testing ARO-INHBE, an siRNA therapy designed to reduce hepatic expression of the INHBE gene, which is linked to lower risk of metabolic disease. Interim results indicate that combining ARO-INHBE with tirzepatide nearly doubled weight loss compared to tirzepatide alone.
Similarly, research teams have experimented with CRISPR to induce GLP-1 expression in vivo, highlighting a broader trend toward genetic interventions in metabolic disorders.
Potential Risks
Gene therapy introduces new challenges absent in conventional medications. Side effects cannot be easily reversed once therapy is administered. Long-term effects of sustained GLP-1 production in the pancreas remain unknown, with some studies warning of potential pancreatic hyperplasia or increased risk of pancreatitis.
Fractyl emphasizes the localized, nutrient-responsive nature of its therapy as a safety feature, but longitudinal studies will be critical to confirm its long-term safety.
Progress Toward Clinical Use
Fractyl recently completed Clinical Trial Applications for RJVA-001 in the EU and Australia, aiming to begin first-in-human dosing later this year. The company is also exploring complementary strategies, including its Revita program—an endoscopic procedure that resurfaces the duodenal lining. In the REMAIN-1 study, patients receiving Revita maintained weight loss even after stopping GLP-1 therapy, unlike those in the sham group who regained weight.
“Weight regain almost always follows the discontinuation of GLP-1 therapy,” said Shelby Sullivan, professor of medicine at Dartmouth University. “These findings suggest duodenal mucosal resurfacing could fill a major gap in obesity care.”
Challenges Ahead
Despite the promise, significant hurdles remain. AAV-based therapies have safety concerns, and one-time gene treatments could cost millions—far exceeding the $1,000–$1,350 monthly cost of existing GLP-1 drugs. Insurance coverage for obesity treatments is already limited, raising questions about accessibility.
Nonetheless, patient interest is high. Fractyl completed enrollment for the REMAIN-1 study in under four months, reflecting strong demand for alternatives to lifelong injections.
As gene therapies advance, obesity care may be poised for a paradigm shift—from chronic medication management to durable, long-term metabolic remission.
